Herclon 150 Mg

Herclon 150 mg Injection is a prescription anticancer medication manufactured by Cipla Ltd., containing the active ingredient Trastuzumab, a monoclonal antibody. It is primarily used to treat HER2-positive breast cancer and metastatic gastric (stomach) cancer.

🧬 How It Works

Trastuzumab targets the HER2 (human epidermal growth factor receptor 2) protein, which is overexpressed in certain cancer cells. By binding to these receptors, it inhibits cancer cell growth and proliferation, leading to tumor shrinkage. This targeted therapy is often administered alongside chemotherapy agents such as paclitaxel, docetaxel, or cisplatin to enhance treatment efficacy.

💉 Administration

• Route: Intravenous infusion.

• Initial Dose: Administered over 90 minutes.

• Subsequent Doses: If well-tolerated, may be given over 30 minutes.

• Monitoring: Regular assessments of heart function are essential during treatment.

⚠️ Side Effects

Common Side Effects:

• Fever, chills, nausea, vomiting

• Headache, dizziness

• Fatigue, muscle or joint pain

• Diarrhea, constipation

• Skin rash, hair loss

• Loss of appetite

Serious Side Effects:

• Heart problems (e.g., congestive heart failure)

• Breathing difficulties, lung inflammation

• Severe allergic reactions

• Kidney issues

Patients are advised to inform their healthcare provider of any pre-existing heart or lung conditions before initiating treatment.